LCTX

Lineage Cell Therapeutics, Inc. LCTX

LCTX
Lineage Cell Therapeutics, Inc. SER
Serina Therapeutics, Inc. MAIA
MAIA Biotechnology, Inc. LRMR
Larimar Therapeutics, Inc. LENZ
LENZ Therapeutics, Inc. LYRA
Lyra Therapeutics, Inc. IMDX
Insight Molecular Diagnostics Inc. LPTX
Leap Therapeutics, Inc. VTGN
VistaGen Therapeutics, Inc. CLSD
Clearside Biomedical, Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode LCTX SER MAIA LRMR LENZ LYRA IMDX LPTX VTGN CLSD
6M 253.34 % 6.41 % 1.33 % 140.88 % 91.46 % 50.10 % 39.93 % 97.07 % 90.09 % -65.30 %
YTD 222.33 % 4.12 % -27.27 % 8.73 % 37.12 % -28.98 % 66.95 % -80.17 % 21.39 % -72.23 %
1Y 93.25 % -21.45 % -38.21 % -39.86 % 52.12 % -31.09 % 24.68 % -72.71 % 33.44 % -77.70 %
3Y 50.91 % -76.77 % -53.52 % 40.65 % 158.60 % -96.86 % -75.03 % -92.59 % 3.33 % -78.07 %
5Y 56.60 % -92.64 % -65.92 % -71.74 % -55.70 % -98.80 % -86.86 % -97.04 % -82.09 % -82.31 %
10Y -51.46 % -94.51 % -65.92 % -98.36 % -55.70 % -99.17 % -97.59 % -99.19 % -98.30 % -96.34 %
From the beginning -57.62 % -94.51 % -65.92 % -98.16 % -55.70 % -99.17 % -97.59 % -99.19 % -99.73 % -96.34 %

Dividend

Lineage Cell Therapeutics, Inc.

LENZ Therapeutics, Inc.